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October 9, 2012:1430–7body size in patients with AF (n  42) using ICE imaging. The
uestion is whether they measured the LAA ostium or just the
AA body size.
Regarding peri-device flow (leak), Viles-Gonzalez et al. (1)
xplained that a peri-device flow would be the mismatch
etween the circular device and the typically oval LAA orifice
nd the subsequent inadequacy of circumferential LAA sealing.
disagree with this explanation of “shape mismatch” conception.
ccurate measurement of maximal LAA ostial diameter is much
ore important than shape, because the LAA ostium is mainly a
oft tissue structure that can be expanded and fit completely to the
evice shape if the device is placed at an optimal location. ICE
AA ostium imaging with color Doppler flow can reliably confirm
he optimal location without any peri-device flow. Of note, to
valuate the peri-device flow (leak), LAA emptying flow is more
mportant than the “fill-in flow,” which was only illustrated in their
igure 2 (1), because such a fill-in flow may be a slight “pit” and
oes not necessarily indicate a flow communicating to the closed
AA (Fig. 1B).
Although the investigators should be congratulated for report-
ng on such a large cohort of patients who underwent LAA device
losure, I found the LAA ostium length measurements biased and
eri-device flow unconfirmed against the patients who had com-
on peri-device flow (leak). These factors significantly impair the
ower of this study and put into question the accuracy of their
onclusion.
ian-Fang Ren, MD*
Division of Cardiovascular Medicine
niversity of Pennsylvania Health System
11 N 9th Street
hiladelphia, Pennsylvania 19107
-mail: jianfren@yahoo.com
Figure 1 Intracardiac Echocardiographic Imaging of Left Atrial
(A) The transducer is placed in the right ventricular outflow tract, showing the LAA
Watchman device (struts, arrows) located at the LAA Os, (B) The transducer is pla
at the LAA Os without peri-device flow seen around the LAA Os side. A blue color
upper left pulmonary vein.http://dx.doi.org/10.1016/j.jacc.2012.04.054EFERENCES
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Reply
We read with interest the letter of Dr. Ren, stating that
accurate echocardiographic measurement of the left atrial ap-
pendage (LAA) anatomy, especially of the ostium, is critically
important for successful LAA ostial closure using the Watch-
man device. In our study, the Core Echocardiography Labora-
tory measured the echocardiographic ostium of the LAA, and
the LAA body size (1). In addition, he expressed disagreement
with the explanation of “shape mismatch,” which consists of an
oval-shaped LAA and a spherical LAA closure device. We
agree that accurate measurement of maximal LAA ostial diam-
eter is of critical importance to obtain adequate seal of the
LAA. We also share the opinion that the LAA ostium is a soft
tissue structure that can be expanded and fit completely to the
device shape if the device is placed at an optimal location.
However, we found in clinical practice and during the study,
that even when we chose a device that was slightly larger,
because the diameter of the LAA ostium is larger in one of the
Appendage (LAA)
(Os; diameter  18 mm, between the two white horizontal arrows) and the
the pulmonary artery (PA), showing the closure device (arrows) properly located
age in the LA side only indicates a slight “pit” region. Ao  aortic root; ulpv (LA)
ostium
ced in
flow imorthogonal axes (i.e., oval shape), a spherical device may not
RR
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October 9, 2012:1430–7completely occlude the ostium. The shape mismatch between
the LAA ostium and the device is clearly evidenced in the
three-dimensional transesophageal echocardiographic images,
such as the one included in our paper (1).
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New Oral Anticoagulants:
Good but Not Good Enough!
In the recent article by the European Society of Cardiology
Working Group on anticoagulants in heart disease (1), the authors
describe in great clarity the emerging data regarding new antico-
agulants for the treatment of nonvalvular atrial fibrillation. In the
closing segment of conclusions and implications, the authors list
their concerns regarding “scientific knowledge gaps” and the lack
of clinical tools (like reversal agents or pharmacodynamic moni-
toring objectives and means). Regrettably, in the name of simplic-
ity (i.e., no pharmacodynamic monitoring or dose adjustment and
rigid dose regimens with a one-size-fits-all strategy), we have
taken potentially great drugs and made them good, but truly not
good enough for some of our individual patients.
Why should we bother with pharmacodynamic studies of these
agents? Numerous known factors (body weight, age, renal func-
tion, liver function, Cyp 3A4, and P-glycoprotein inhibitors and
inducers) and probably many unknown factors interact with these
agents to create heterogeneous effect on plasma levels and coagu-
lation profile. Because these agents are meant to be lifelong
prescriptions, they probably command the effort of knowing how
the individual patient responds to the prescribed agent and dose.
This is especially true because we have the option of prescribing
alternative drugs and doses to suit the individual patient best.
Major bleeding is the most common complication of these
agents in patients with nonvalvular atrial fibrillation (exceeding in
most current studies the rate of clinical thromboembolism) and
probably can be reduced by individualized drug prescribing and
dosing based on individual pharmacokinetic and pharmacody-
namic studies. Further, thromboembolism and stroke possibly
related to therapeutic failure potentially can be reduced by moni-
toring and dose adjustments to enhance efficacy.Should we decide to extend the use of these agents to other
patient subsets (valvular atrial fibrillation, mechanical valves, hy-
percoagulable states), establishing monitoring protocols and delin-
eating the therapeutic targets may facilitate the design of future
clinical trials and may optimize both efficacy and safety. As an
example, in the PETRO (Prevention of Embolic and ThROm-
botic events study) among patients receiving dabigatran 150 mg
twice daily, there was an approximately 7-fold difference in
between the fifth and 95th percentile in both peak (95% confidence
interval: 64 to 443 ng/ml) and trough (95% confidence interval: 31
to 225 ng/ml) plasma levels (2). This 7-fold difference translates
into significantly higher exposure, thrombin time, and bleeding
risk. On the other end of the spectrum, approximately 15% of the
patients had peak activated partial thromboplastin time of 40 s.
Future research should attempt to delineate: 1) the best phar-
macodynamic monitoring tools for dabigatran (2) and Xa inhibi-
tors (3,4); 2) the best monitoring protocol (5) (including timing
relative to dosing and frequency); and 3) the best therapeutic
targets. It is very likely that by using these strategies, we could
enhance further the efficacy and safety of these agents and could
extend their use to new indications.
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Reply
We thank Dr. Kaluski and colleagues for their thoughts on the
possibility of individualizing dosing strategies for the new oral
anticoagulants. From a theoretical perspective, the one-size-
fits-all strategy seems not to be ideal, because of the potential
pharmacokinetic interactions, the variability in drug metabo-
lism during lifelong administration, and the inherent risks of
thrombosis in the case of underdosing or of bleeding in the case
of overdosing. For this reason, we favored the European
